
<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/joey/Project/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<encodingDesc>
			<appInfo>
				<application version="0.4.2-SNAPSHOT" ident="GROBID" when="2017-08-10T23:30+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Structural bioinformatics e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2012">2012</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName>
								<forename type="first">Emilie</forename>
								<surname>Pihan</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="laboratory">Institut de Pharmacologie Moléculaire et Cellulaire</orgName>
								<orgName type="institution" key="instit1">CNRS UMR7275</orgName>
								<orgName type="institution" key="instit2">Université Nice – Sophia Antipolis</orgName>
								<address>
									<postCode>660, 06560</postCode>
									<settlement>Valbonne</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Lionel</forename>
								<surname>Colliandre</surname>
							</persName>
							<affiliation key="aff1">
								<orgName type="department">Centre de Biochimie Structurale</orgName>
								<orgName type="institution" key="instit1">INSERM U1054</orgName>
								<orgName type="institution" key="instit2">CNRS UMR5048 – Université</orgName>
								<address>
									<addrLine>Montpellier 1 et 2</addrLine>
									<settlement>Montpellier</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Jean-François</forename>
								<surname>Guichou</surname>
							</persName>
							<affiliation key="aff1">
								<orgName type="department">Centre de Biochimie Structurale</orgName>
								<orgName type="institution" key="instit1">INSERM U1054</orgName>
								<orgName type="institution" key="instit2">CNRS UMR5048 – Université</orgName>
								<address>
									<addrLine>Montpellier 1 et 2</addrLine>
									<settlement>Montpellier</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Dominique</forename>
								<surname>Douguet</surname>
							</persName>
							<affiliation key="aff1">
								<orgName type="department">Centre de Biochimie Structurale</orgName>
								<orgName type="institution" key="instit1">INSERM U1054</orgName>
								<orgName type="institution" key="instit2">CNRS UMR5048 – Université</orgName>
								<address>
									<addrLine>Montpellier 1 et 2</addrLine>
									<settlement>Montpellier</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Structural bioinformatics e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design</title>
					</analytic>
					<monogr>
						<title level="j" type="main">BIOINFORMATICS APPLICATIONS NOTE</title>
						<imprint>
							<biblScope unit="volume">28</biblScope>
							<biblScope unit="issue">11</biblScope>
							<biblScope unit="page" from="1540" to="1541"/>
							<date type="published" when="2012">2012</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1093/bioinformatics/bts186</idno>
					<note type="submission">Received on December 7, 2011; revised on March 30, 2012; accepted on April 5, 2012</note>
					<note>Associate Editor: Anna Tramontano Contact: douguet@ipmc.cnrs.fr Supplementary information: Supplementary data are available at Bioinformatics online.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract>
				<p>Motivation: In the drug discovery field, new uses for old drugs, selective optimization of side activities and fragment-based drug design (FBDD) have proved to be successful alternatives to high-throughput screening. e-Drug3D is a database of 3D chemical structures of drugs that provides several collections of ready-to-screen SD files of drugs and commercial drug fragments. They are natural inputs in studies dedicated to drug repurposing and FBDD. Availability: e-Drug3D collections are freely available at http://chemoinfo.ipmc.cnrs.fr/e-drug3d.html either for download or for direct in silico web-based screenings.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">INTRODUCTION</head><p>Approved drugs represent very attractive and valuable starting point for drug discovery. Studies of drugs entering the market show that most of their drug progenitors (or lead structures) were known drugs or clinical candidates (<ref type="bibr" target="#b10">Proudfoot, 2002;</ref><ref type="bibr" target="#b12">Teague, 2011</ref>). The rationale is that a drug usually acts on more than one target and may exhibit previously unknown functions due to promiscuous off-target interactions explaining efficacy and/or side-effects (<ref type="bibr" target="#b0">Campillos et al., 2008</ref>). Examples of new therapeutic indications for old drugs include the anti-emetic and hypnotic Thalidomide originally withdrawn as a leprostatic agent (<ref type="bibr" target="#b13">Teo et al., 2005</ref>) or the anti-neoplastic Finasteride for the treatment of hair loss (approved in 1997). Over the years, an increasing number of pharmaceutical companies have been interested in 'drug repurposing' in order to reduce the risk and cost of the development of new chemical entities (<ref type="bibr" target="#b14">Tobinick, 2009</ref>). The fragment-based drug design (FBDD) approach represents another validated alternative to high-throughput screening (<ref type="bibr" target="#b9">Murray and Blundell, 2010</ref>). It consists of identifying low molecular weight molecules that are able to interact with a defined binding site. Hits are then combined or grown into high-affinity ligands. Over the past decade, FBDD has become established as an effective approach and has led to the discovery of high-affinity bioactive molecules, some of which are in clinical development. The 'rule of three' provides a useful guideline when designing the fragment * To whom correspondence should be addressed. screening collection (<ref type="bibr" target="#b1">Congreve et al., 2003</ref>), but the selection criteria may also include 'privileged structures' that are commonly found in known drug molecules (<ref type="bibr" target="#b6">Hartshorn et al., 2005;</ref><ref type="bibr" target="#b8">Lepre, 2001</ref>). This strategy is based on the assumption that molecules resembling existing drugs are more likely to possess appropriate ADMET properties than random molecules. e-Drug3D has been purposely designed to provide free and ready-to-screen virtual collections of approved drugs and of their commercially available substructures (fragments). These collections of compounds are natural inputs for various cheminformatic and virtual screening applications.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">e-DRUG3D COLLECTIONS</head><p>e-Drug3D is an annotated database based on the 'Drugs@FDA Data File' released by the US Food and Drug Administration (FDA). Over the years, several publicly available and drug-specific databases have emerged including DrugBank (<ref type="bibr" target="#b7">Knox et al., 2011</ref>), ChEMBL/Drugs (<ref type="bibr" target="#b3">Gaulton et al., 2012</ref>) and SuperDrug (<ref type="bibr" target="#b4">Goede et al., 2005</ref>). SuperDrug was the first free resource that provided 3D conformers of drug structures. In developing e-Drug3D, our objective was to further expand such computed drug structures by adding recent approved drugs and providing a collection of commercially available drug fragments. e-Drug3D currently contains 1519 annotated 3D structures of 1305 different FDAapproved drugs of molecular weight &lt;2000 (last update: June 2011). Chiral centers are checked and enantiomers are differentiated. We also provide two supplementary collections resulting from</p><p>(i) the calculation of the most probable tautomeric and ionic states at pH 7.4 and (ii) the generation of multiple conformations for ring systems. Finally, we produced a collection of commercial substructures of drugs. The current collection contains 1383 commercial fragments that are represented by a single conformation. Preparation, analyses and comparisons of the two collections are given in the Supplementary Material. The e-Drug3D database is accessible through our web interface for browsing. It can be queried by keyword search, structural criteria or similarity search. Tools are also provided to select subsets of drugs for comparisons. Drug and fragment collections are directly linked to the in silico screening web server e-LEA3D (<ref type="bibr">Douguet, 2010</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">A FBDD EXAMPLE</head><p>The FBDD approach was successfully used to identify novel inhibitors of human cyclophilins. These proteins are enzymes exhibiting a peptidyl-prolyl cis–trans isomerase activity and playinga role in immunity and viral infection, including Hepatitis C virus (HCV;<ref type="bibr" target="#b5">Guichou et al., 2011;</ref><ref type="bibr" target="#b15">Watashi, 2010</ref>). Several fragments were selected by virtual screening and soaked with cyclophilin D crystals (<ref type="bibr" target="#b11">Schlatter et al., 2005</ref>). Among them, the compound 1-formylpiperazine corresponds to one fragment of our drug collection that is a substructure of the drugs Delavirdine, Doxazosin, Prazosin and Terazosin.<ref type="figure" target="#fig_0">Figure 1</ref>shows the structure of the human cyclophilin D with this fragment (PDB ID 3RCK). Chemical optimization of several co-crystallized hit fragments led to the identification of submicromolar inhibitors of cyclophilin A, B and D (<ref type="bibr" target="#b5">Guichou et al., 2011</ref>). These molecules show similar inhibition in infectious models and no cytotoxicity at the effective concentrations. The discovery of non-peptidic cyclophilin inhibitors is a breakthrough in the ongoing search for new anti-HCV agents as well as a successful example of the application of FBDD to difficult targets.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>e-Drug3D</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig.1.</head><figDesc>Fig. 1. (a) View of the 3D surface of the human cyclophilin D complexed with 1-formylpiperazine (PDB ID 3RCK). The fragment is represented by its electronic density in blue (map contour at 1.0 σ ). (b) Residues implicated in the binding are shown along with the hydrogen bond between the carbonyl moiety of 1-formylpiperazine and the backbone nitrogen of residue Asn102. Inset— 2D sketch of 1-formylpiperazine. Pictures were generated by using the program Pymol.</figDesc></figure>

			<note place="foot">© The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com at :: on August 30, 2016 http://bioinformatics.oxfordjournals.org/ Downloaded from</note>

			<note place="foot">at :: on August 30, 2016 http://bioinformatics.oxfordjournals.org/ Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENT</head><p>We thank D.Barbier for his help in managing the web server.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct   xml:id="b0">
	<analytic>
		<title level="a" type="main">Drug target identification using side-effect similarity</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<surname>Campillos</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">321</biblScope>
			<biblScope unit="page" from="263" to="266" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b1">
	<analytic>
		<title level="a" type="main">A &apos;rule of three&apos; for fragment-based lead discovery?</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<surname>Congreve</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Discov. Today</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="876" to="877" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b2">
	<analytic>
		<title level="a" type="main">2010) e-LEA3D: a computational-aided drug design web server</title>
		<author>
			<persName>
				<forename type="first">D</forename>
				<surname>Douguet</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="615" to="621" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b3">
	<analytic>
		<title level="a" type="main">ChEMBL: a large-scale bioactivity database for drug discovery</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Gaulton</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1100" to="1107" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b4">
	<analytic>
		<title level="a" type="main">SuperDrug: a conformational drug database</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Goede</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1751" to="1753" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b5">
	<monogr>
		<title level="m" type="main">New inhibitors of cyclophilins and uses thereof</title>
		<author>
			<persName>
				<forename type="first">J.-F</forename>
				<surname>Guichou</surname>
			</persName>
		</author>
		<imprint>
			<date type="published" when="2011" />
		</imprint>
	</monogr>
	<note>Patent. WO2011076784</note>
</biblStruct>

<biblStruct   xml:id="b6">
	<analytic>
		<title level="a" type="main">Fragment-based lead discovery using X-ray crystallography</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">J</forename>
				<surname>Hartshorn</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="403" to="413" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b7">
	<analytic>
		<title level="a" type="main">DrugBank 3.0: a comprehensive resource for &apos;omics&apos; research on drugs</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<surname>Knox</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1035" to="1041" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b8">
	<analytic>
		<title level="a" type="main">Library design for NMR-based screening</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<forename type="middle">A</forename>
				<surname>Lepre</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Discov. Today</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="133" to="140" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b9">
	<analytic>
		<title level="a" type="main">Structural biology in fragment-based drug design</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<forename type="middle">W</forename>
				<surname>Murray</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">T</forename>
				<forename type="middle">L</forename>
				<surname>Blundell</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Opin. Struct. Biol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="497" to="507" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b10">
	<analytic>
		<title level="a" type="main">Drugs, leads and drug-likeness: an analysis of some recently launched drugs</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">R</forename>
				<surname>Proudfoot</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioorg. Med. Chem. Lett</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1647" to="1650" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b11">
	<analytic>
		<title level="a" type="main">Crystal engineering yields crystals of cyclophilin D diffracting to 1.7 A resolution</title>
		<author>
			<persName>
				<forename type="first">D</forename>
				<surname>Schlatter</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Crystallogr. D</title>
		<imprint>
			<biblScope unit="page" from="61" to="513" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b12">
	<analytic>
		<title level="a" type="main">Learning lessons from drugs that have recently entered the market</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<forename type="middle">J</forename>
				<surname>Teague</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Discov. Today</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="398" to="411" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b13">
	<analytic>
		<title level="a" type="main">Thalidomide as a novel therapeutic agent: new uses for an old product</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<forename type="middle">K</forename>
				<surname>Teo</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Discov. Today</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="107" to="114" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b14">
	<analytic>
		<title level="a" type="main">The value of drug repositioning in the current pharmaceutical market</title>
		<author>
			<persName>
				<forename type="first">E</forename>
				<forename type="middle">L</forename>
				<surname>Tobinick</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug News Perspect</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="119" to="125" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b15">
	<analytic>
		<title level="a" type="main">Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection</title>
		<author>
			<persName>
				<forename type="first">K</forename>
				<surname>Watashi</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr. Opin. Investig. Drugs</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="213" to="224" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>